Table 1 Immunogenicity of Influenza H3N2 vaccine in juvenile systemic erythematosus (JSLE) patients and healthy controls
JSLE (n = 24) | Healthy controls (n = 29) | P | |
|---|---|---|---|
Before immunization | |||
Seroprotection rate, n (%) | 22 (91.7) | 25 (86.2) | 0.678 |
GMT, value (95% CI) | 102.3 (75.0–139.4) | 109.6 (68.2–176.2) | 0.231 |
After immunization | |||
Seroprotection rate, n (%) | 24 (100) | 28 (96.6) | 1.000 |
Seroconversion rate, n (%) | 4 (16.7) | 9 (31.0) | 0.338 |
GMT, value (95% CI) | 162.3* (132.9–198.3) | 208.1* (150.5–287.8) | 0.143 |
Factor increase in GMT | 1.6 (1.2–2.1) | 1.9 (1.4–2.5) | 0.574 |